StockData
Prelude Therapeutics Inc logo

Prelude Therapeutics Inc (PRLD) income statement

PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/3053% above fair value
$3.25−0.04 (-1.36%)

Close on Nov 19, 2026Market cap $259.76MP/E –Yield –

See a number that looks wrong?